CSF3R-T618I has become an established biomarker facilitating CNL diagnosis and also provides a therapeutic target for treatment with the JAK1/2 inhibitor ruxolitinib [4,5,6]. This evidence concerns the gene CSF3R and chronic neutrophilic leukemia.